http://www.zibb.com/all/theme/cq/Vical+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Wed, 25 Nov 2009 12:05:52 GMTWed, 25 Nov 2009 12:05:52 GMT608831http://www.zibb.com/all/theme/cq/Vical+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.apria.com/resources/1,2725,494-853310,00.htmlSAN DIEGO, Dec 01, 2008 /PRNewswire-FirstCall via COMTEX/ -- Vical Incorporated (Nasdaq: VICL) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc.http://www.apria.com/resources/1,2725,494-853310,00.htmlVical Incorporatedhttp://www.vical.com/about/history.htmSkip to content Vical About About Us Home Management History Careers Job Openings How To Apply Directions Technology Technology Home Patents Reagents Publications Allovectin-7 Publications Vaxfectin Publications Products Products Home Infectious Diseases CMV Influenza Vaxfectin® Cancer Therapieshttp://www.vical.com/about/history.htmVical Incorporatedhttp://www.quotelinks.com/companies/vicl.htmlStock quotes, news and charts for Vical Incorporated Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/vicl.htmlVical Incorporatedhttp://www.biospace.com/news_story.aspx?NewsEntityId=20295The Phase 1, open-label clinical trial study was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center.http://www.biospace.com/news_story.aspx?NewsEntityId=20295Vical Incorporatedhttp://www.jonesday.com/experience/experience_detail.aspx?exID=S10822Summary: Purchase of $22.6 million of Common Stock in a private placement by Vical Incorporated.http://www.jonesday.com/experience/experience_detail.aspx?exID=S10822Vical Incorporatedhttp://www.apria.com/resources/1,2725,494-858424,00.htmlVical Incorporated (NASDAQ: VICL) announced the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine.http://www.apria.com/resources/1,2725,494-858424,00.htmlVical Incorporatedhttp://www.biospace.com/company_profile.aspx?CompanyID=2849BioSpace.com Search the Site News Jobs Companies Events Employers Post Job | Search Resumes Visit BioSpace.com Medical Device and Diagnostics Channel HOME spacer CAREER NETWORK spacer NEWS spacer HOTBEDS spacer EVENT CENTER spacer CAREER FAIRS spacer COMPANY PROFILES spacer BIOPHARM INSIGHT spacerhttp://www.biospace.com/company_profile.aspx?CompanyID=2849Vical Incorporatedhttp://www.vical.com/investors/corporate/board.htmWe have three classes of directors serving staggered three-year terms. Each class currently consists of two directors. Our Board is presently composed of five directors. One Class II director seat is vacant.http://www.vical.com/investors/corporate/board.htmVical Incorporatedhttp://www.biospace.com/news_story.aspx?StoryID=45249&full=1SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that Larry R. Smith, Ph.D., Vical's Vice President of Vaccine Research, will participate in a panel discussion at 9:30 a.m.http://www.biospace.com/news_story.aspx?StoryID=45249&full=1Vical Incorporatedhttp://www.biospace.com/news_story.aspx?StoryID=20072&full=1SAN DIEGO, May 29 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company will report terms of a collaborative agreement with AnGes MG, Inc.http://www.biospace.com/news_story.aspx?StoryID=20072&full=1Vical Incorporated